AmpliPhi raises $7m in placement
Bacteriophage-based treatment company AmpliPhi Biosciences has completed a $7 million private placement to fund its development activities.
The financing round was led by established life sciences investors RA Capital Management and Third Security. BioScience Managers also participated.
“We are very pleased to have the support of these outstanding life science investors,” AmpliPhi CEO Philip J Young said.
As part of its investment, Third Security will appoint managing director Julian P Kirk to the AmpliPhi board. Existing AmpliPhi board members Dr Caroline Williams and Tony Gellert have meanwhile stepped down.
US-based AmpliPhi last year merged with Australia’s Special Phage Services. Gellert had joined the board as a result of this merger.
The combined company is focused on developing antibacterial treatments for antibiotic-resistant bacterial infections. Its lead program centres on treatments for chronic and acute lung infections.
Even non-antibiotics can disrupt the microbiome
Many non-antibiotics inhibit useful gut bacteria, giving rise to an imbalance in the microbiome,...
How brain stem cells move between resting and active states
Understanding this process is crucial, because it underpins how the brain repairs itself and...
Accurate age estimation with DNA methylation
Using cutting-edge artificial intelligence, scientists created a tool that can determine a...
